Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.

Leukemia & lymphoma - 1 Jan 2013

Konoplev Sergej, Yin C Cameron, Kornblau Steven M, Kantarjian Hagop M, Konopleva Marina, Andreeff Michael, Lu Gary, Zuo Zhuang, Luthra Rajyalakshmi, Medeiros L Jeffrey, Bueso-Ramos Carlos E

Abstract excerpt

Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) is a controversial diagnosis, as others propose that it represents chronic myelogenous leukemia in blast phase (CML-BP). NPM1 mutations occur in 25-35% of patients with AML but are absent in patients with CML. Conversely, ABL1 mutations occur in 25% of imatinib-naive patients with CML-BP but are not described in patients with AML. We analyzed for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abnormal Karyotype
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow

Share to Fusion Proteins, bcr-abl

Share to Genes, abl

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Philadelphia Chromosome

Source

Open in PubMed Open full text

Identifiers

PMID: 22691121
DOI: 10.3109/10428194.2012.701739
PMCID: PMC3925981

Genes

ABL1
NPM1
AKT1
AKT2
AKT3
BRAF
EGFR
GNAQ
GNAS
IDH1
IDH2
KRAS
MET
NRAS
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.PMID 22691121Read ↗

Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.Semantic proximity Read ↗

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).Semantic proximity Read ↗

Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.Semantic proximity Read ↗

Clinical characteristics of Philadelphia positive T‐cell lymphoid leukemias—(De novo and blast phase CML)Semantic proximity Read ↗

Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.Semantic proximity Read ↗

Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.Semantic proximity Read ↗

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemiaSemantic proximity Read ↗

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.Semantic proximity Read ↗

B-lymphoid/myeloid stem cell origin in Ph-positive acute leukemia with myeloid markers.Semantic proximity Read ↗

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8Semantic proximity Read ↗

Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical courseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.